Global Meningococcal Group A and C Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 70

Published Date: 01 Jul 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Meningococcal Group A and C Conjugate Vaccine market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Meningococcal Group A and C Conjugate Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Meningococcal Group A and C Conjugate Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Meningococcal Group A and C Conjugate Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Meningococcal Group A and C Conjugate Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Meningococcal Group A and C Conjugate Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Meningococcal Group A and C Conjugate Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Meningococcal Group A and C Conjugate Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Meningococcal Group A and C Conjugate Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Prefilled
    Non-prefilled

Market segment by Application
    Adults
    Children

Major players covered
    Sanofi Pasteur
    GSK
    Pfizer
    Chongqing Zhifei Biological Products

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Meningococcal Group A and C Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Meningococcal Group A and C Conjugate Vaccine, with price, sales quantity, revenue, and global market share of Meningococcal Group A and C Conjugate Vaccine from 2019 to 2024.
Chapter 3, the Meningococcal Group A and C Conjugate Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Group A and C Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Meningococcal Group A and C Conjugate Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Meningococcal Group A and C Conjugate Vaccine.
Chapter 14 and 15, to describe Meningococcal Group A and C Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Prefilled
        1.3.3 Non-prefilled
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Adults
        1.4.3 Children
    1.5 Global Meningococcal Group A and C Conjugate Vaccine Market Size & Forecast
        1.5.1 Global Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity (2019-2030)
        1.5.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Sanofi Pasteur
        2.1.1 Sanofi Pasteur Details
        2.1.2 Sanofi Pasteur Major Business
        2.1.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product and Services
        2.1.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Sanofi Pasteur Recent Developments/Updates
    2.2 GSK
        2.2.1 GSK Details
        2.2.2 GSK Major Business
        2.2.3 GSK Meningococcal Group A and C Conjugate Vaccine Product and Services
        2.2.4 GSK Meningococcal Group A and C Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 GSK Recent Developments/Updates
    2.3 Pfizer
        2.3.1 Pfizer Details
        2.3.2 Pfizer Major Business
        2.3.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Product and Services
        2.3.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Pfizer Recent Developments/Updates
    2.4 Chongqing Zhifei Biological Products
        2.4.1 Chongqing Zhifei Biological Products Details
        2.4.2 Chongqing Zhifei Biological Products Major Business
        2.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product and Services
        2.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Chongqing Zhifei Biological Products Recent Developments/Updates

3 Competitive Environment: Meningococcal Group A and C Conjugate Vaccine by Manufacturer
    3.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Meningococcal Group A and C Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Meningococcal Group A and C Conjugate Vaccine Manufacturer Market Share in 2023
        3.4.3 Top 6 Meningococcal Group A and C Conjugate Vaccine Manufacturer Market Share in 2023
    3.5 Meningococcal Group A and C Conjugate Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Meningococcal Group A and C Conjugate Vaccine Market: Region Footprint
        3.5.2 Meningococcal Group A and C Conjugate Vaccine Market: Company Product Type Footprint
        3.5.3 Meningococcal Group A and C Conjugate Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region
        4.1.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Region (2019-2030)
    4.2 North America Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030)
    4.3 Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030)
    4.5 South America Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030)
    4.6 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Type (2019-2030)
    5.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application (2019-2030)
    6.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country
        7.3.1 North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country
        8.3.1 Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Market Size by Region
        9.3.1 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America Meningococcal Group A and C Conjugate Vaccine Market Size by Country
        10.3.1 South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Market Size by Country
        11.3.1 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Meningococcal Group A and C Conjugate Vaccine Market Drivers
    12.2 Meningococcal Group A and C Conjugate Vaccine Market Restraints
    12.3 Meningococcal Group A and C Conjugate Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Meningococcal Group A and C Conjugate Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Meningococcal Group A and C Conjugate Vaccine
    13.3 Meningococcal Group A and C Conjugate Vaccine Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Meningococcal Group A and C Conjugate Vaccine Typical Distributors
    14.3 Meningococcal Group A and C Conjugate Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
 Table 4. Sanofi Pasteur Major Business
 Table 5. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product and Services
 Table 6. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Sanofi Pasteur Recent Developments/Updates
 Table 8. GSK Basic Information, Manufacturing Base and Competitors
 Table 9. GSK Major Business
 Table 10. GSK Meningococcal Group A and C Conjugate Vaccine Product and Services
 Table 11. GSK Meningococcal Group A and C Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. GSK Recent Developments/Updates
 Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 14. Pfizer Major Business
 Table 15. Pfizer Meningococcal Group A and C Conjugate Vaccine Product and Services
 Table 16. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. Pfizer Recent Developments/Updates
 Table 18. Chongqing Zhifei Biological Products Basic Information, Manufacturing Base and Competitors
 Table 19. Chongqing Zhifei Biological Products Major Business
 Table 20. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product and Services
 Table 21. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 22. Chongqing Zhifei Biological Products Recent Developments/Updates
 Table 23. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024) & (K Units)
 Table 24. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 25. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 26. Market Position of Manufacturers in Meningococcal Group A and C Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 27. Head Office and Meningococcal Group A and C Conjugate Vaccine Production Site of Key Manufacturer
 Table 28. Meningococcal Group A and C Conjugate Vaccine Market: Company Product Type Footprint
 Table 29. Meningococcal Group A and C Conjugate Vaccine Market: Company Product Application Footprint
 Table 30. Meningococcal Group A and C Conjugate Vaccine New Market Entrants and Barriers to Market Entry
 Table 31. Meningococcal Group A and C Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
 Table 32. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 33. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
 Table 34. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
 Table 35. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 36. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 37. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Region (2019-2024) & (US$/Unit)
 Table 38. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Region (2025-2030) & (US$/Unit)
 Table 39. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 40. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 41. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Type (2019-2024) & (USD Million)
 Table 42. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Type (2025-2030) & (USD Million)
 Table 43. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Type (2019-2024) & (US$/Unit)
 Table 44. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Type (2025-2030) & (US$/Unit)
 Table 45. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 46. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 47. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application (2019-2024) & (USD Million)
 Table 48. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application (2025-2030) & (USD Million)
 Table 49. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Application (2019-2024) & (US$/Unit)
 Table 50. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Application (2025-2030) & (US$/Unit)
 Table 51. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 52. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 53. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 54. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 55. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 56. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 57. North America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 58. North America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 59. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 60. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 61. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 62. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 63. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 64. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 65. Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 66. Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 67. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 68. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 69. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 70. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 71. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
 Table 72. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
 Table 73. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 74. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 75. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 76. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 77. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 78. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 79. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 80. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 81. South America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 82. South America Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 83. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 84. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 85. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 86. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 87. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 88. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 89. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 90. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 91. Meningococcal Group A and C Conjugate Vaccine Raw Material
 Table 92. Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine Raw Materials
 Table 93. Meningococcal Group A and C Conjugate Vaccine Typical Distributors
 Table 94. Meningococcal Group A and C Conjugate Vaccine Typical Customers


List of Figures
 Figure 1. Meningococcal Group A and C Conjugate Vaccine Picture
 Figure 2. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type in 2023
 Figure 4. Prefilled Examples
 Figure 5. Non-prefilled Examples
 Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application in 2023
 Figure 8. Adults Examples
 Figure 9. Children Examples
 Figure 10. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 11. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 12. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity (2019-2030) & (K Units)
 Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Price (2019-2030) & (US$/Unit)
 Figure 14. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2023
 Figure 15. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Manufacturer in 2023
 Figure 16. Producer Shipments of Meningococcal Group A and C Conjugate Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 17. Top 3 Meningococcal Group A and C Conjugate Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 18. Top 6 Meningococcal Group A and C Conjugate Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 19. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 20. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 21. North America Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 22. Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 23. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 24. South America Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 25. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 26. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 27. Global Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Type (2019-2030)
 Figure 28. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Type (2019-2030) & (US$/Unit)
 Figure 29. Global Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 30. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2019-2030)
 Figure 31. Global Meningococcal Group A and C Conjugate Vaccine Average Price by Application (2019-2030) & (US$/Unit)
 Figure 32. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 33. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 34. North America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 35. North America Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 36. United States Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 37. Canada Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 38. Mexico Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 39. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 40. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 41. Europe Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 42. Europe Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 43. Germany Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 44. France Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 45. United Kingdom Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 46. Russia Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 47. Italy Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 48. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 49. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 50. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 51. Asia-Pacific Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 52. China Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 53. Japan Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 54. South Korea Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 55. India Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 56. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 57. Australia Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 58. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 59. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 60. South America Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 61. South America Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 62. Brazil Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 63. Argentina Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 64. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 65. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 66. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 67. Middle East & Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 68. Turkey Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 69. Egypt Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 70. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 71. South Africa Meningococcal Group A and C Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 72. Meningococcal Group A and C Conjugate Vaccine Market Drivers
 Figure 73. Meningococcal Group A and C Conjugate Vaccine Market Restraints
 Figure 74. Meningococcal Group A and C Conjugate Vaccine Market Trends
 Figure 75. Porters Five Forces Analysis
 Figure 76. Manufacturing Cost Structure Analysis of Meningococcal Group A and C Conjugate Vaccine in 2023
 Figure 77. Manufacturing Process Analysis of Meningococcal Group A and C Conjugate Vaccine
 Figure 78. Meningococcal Group A and C Conjugate Vaccine Industrial Chain
 Figure 79. Sales Channel: Direct to End-User vs Distributors
 Figure 80. Direct Channel Pros & Cons
 Figure 81. Indirect Channel Pros & Cons
 Figure 82. Methodology
 Figure 83. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Sanofi Pasteur
GSK
Pfizer
Chongqing Zhifei Biological Products

Related Reports

Global Meningococcal Group A and C Conjugate Vaccine Supply, Demand and Key Producers, 2024-2030

Global Meningococcal Group A and C Conjugate Vaccine Supply, Demand and Key Producers, 2024-2030

date 01 Jul 2024

date Pharma & Healthcare

The global Meningococcal Group A and C Conjugate Vaccine market size is expected to reach $ million by 2030, rising at a market growth of %CAGR during the forecast period (2024-2030).

Product Tags

Meningococcal Group A and C Conjugate Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>